Hepatitis C is a virus that affects the liver. It is transmitted through blood to blood contact. Without treatment, people often develop chronic (long-term) infections which can lead to some developing serious liver disease.

Effective new treatments, called direct acting antivirals (DAAs), are now subsidised on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adults with chronic hepatitis C. DAAs cure hepatitis C in over 95% of cases, with minimal side effects. Tablets need to be taken for only 8-12 weeks for most people. Successful hepatitis C treatment improves liver health by preventing further liver inflammation and cirrhosis. Following treatment some of the damage that has already occurred may repair. Once the virus has been cleared the treated person is no longer infectious for hepatitis C.
Following the introduction of DAAs on the PBS, NSW Health has set a goal for the elimination of hepatitis C by 2028. People living with hepatitis C are strongly recommended to see their general practitioner about hepatitis C treatment.

Further information

For further information please see the fact sheet or contact your local public health unit on 1300 066 055.

Also see the Hepatitis C resources page.​

​​​​​
Page Updated: Monday 29 July 2019
Contact page owner: Communicable Diseases